Gonzalo Rodríguez Martínez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gonzalo Rodríguez Martínez has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Fernández
Department of Restorative Dentistry, Facultad de Odontologia Universidad de Chile Santiago Chile
3 shared publications - Rodrigo Cabello Ibacache
Faculty of Dentistry, Dental School, University of Chile, Santiago, 8380544, Chile
3 shared publications - Alain Manuel Chaple Gil
Facultad de Ciencias de la Salud Carrera de Odontología Grupo de Investigación en Rehabilitación Oral Basada en Evidencia (GIROBE) Universidad Autónoma de Chile Santiago Chile
2 shared publications - Cristian Bersezio
Department of Restorative Dentistry Faculty of Dentistry, University of Chile Santiago Chile
2 shared publications - Rafael Contador
Department of Restorative Dentistry, Faculty of Dentistry, University of Chile, Olivos 943, Santiago, 7500505, Chile, +56 2 2978 5050
2 shared publications - Alfredo von Marttens
Faculty of Dentistry, Dental School, University of Chile, Santiago 8380544, Chile
1 shared publication
Latest Publications
- 18 February 2026
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 30 (2) , 82
Probiotic supplementation and dental caries prevention in children and adolescents: a systematic review of strain-specific and context-dependent effects
Objectives This systematic review evaluates whether probiotic supplementation may provide adjunctive, strain-specific benefits in the prevention and modulation of dental caries outcomes in children and adolescents. The primary outcomes analyzed included caries incidence, lesion progression or regression (ICDAS, dmfs/DMFS), and microbiological parameters such as Streptococcus mutans and Lactobacillus counts. Materials and methods A comprehensive literature search was performed following PRISMA 2020 guidelines across PubMed, Scopus, Web of Science, Cochrane Library, and EMBASE. Randomized controlled trials comparing probiotic interventions with placebo or standard care were included. Two reviewers independently performed study selection, data extraction, and risk of bias assessment using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Randomized Controlled Trials. Due to considerable clinical and methodological heterogeneity among studies particularly in probiotic strain, dosage, delivery vehicle, and outcome measurement a narrative synthesis was undertaken in accordance with JBI guidance. Results Twelve randomized controlled trials met the inclusion criteria. Probiotic supplementation, particularly with Lactobacillus rhamnosus SP1 and L. paracasei SD1 administered via milk or tablets for 6–10 months, significantly reduced caries incidence and S. mutans counts compared with control groups. Evidence regarding the prevention of caries recurrence (secondary prevention) and the regression of white spot lesions in orthodontic patients was limited and inconsistent. The overall certainty of evidence, assessed using GRADE/ConQual, was moderate for primary prevention and low for secondary outcomes. Conclusions Probiotic supplementation may provide modest, strain-specific adjunctive benefits for caries prevention in high-risk pediatric populations; however, the certainty of evidence remains moderate to low, and findings are inconsistent across strains, delivery vehicles, and outcomes. Clinical relevance The findings support the biological plausibility of probiotics in caries management and suggest a potential adjunctive role within preventive dentistry strategies, particularly in selected high-risk populations.
- 18 February 2026
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 30 (2) , 82
Probiotic supplementation and dental caries prevention in children and adolescents: a systematic review of strain-specific and context-dependent effects
Objectives This systematic review evaluates whether probiotic supplementation may provide adjunctive, strain-specific benefits in the prevention and modulation of dental caries outcomes in children and adolescents. The primary outcomes analyzed included caries incidence, lesion progression or regression (ICDAS, dmfs/DMFS), and microbiological parameters such as Streptococcus mutans and Lactobacillus counts. Materials and methods A comprehensive literature search was performed following PRISMA 2020 guidelines across PubMed, Scopus, Web of Science, Cochrane Library, and EMBASE. Randomized controlled trials comparing probiotic interventions with placebo or standard care were included. Two reviewers independently performed study selection, data extraction, and risk of bias assessment using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Randomized Controlled Trials. Due to considerable clinical and methodological heterogeneity among studies particularly in probiotic strain, dosage, delivery vehicle, and outcome measurement a narrative synthesis was undertaken in accordance with JBI guidance. Results Twelve randomized controlled trials met the inclusion criteria. Probiotic supplementation, particularly with Lactobacillus rhamnosus SP1 and L. paracasei SD1 administered via milk or tablets for 6–10 months, significantly reduced caries incidence and S. mutans counts compared with control groups. Evidence regarding the prevention of caries recurrence (secondary prevention) and the regression of white spot lesions in orthodontic patients was limited and inconsistent. The overall certainty of evidence, assessed using GRADE/ConQual, was moderate for primary prevention and low for secondary outcomes. Conclusions Probiotic supplementation may provide modest, strain-specific adjunctive benefits for caries prevention in high-risk pediatric populations; however, the certainty of evidence remains moderate to low, and findings are inconsistent across strains, delivery vehicles, and outcomes. Clinical relevance The findings support the biological plausibility of probiotics in caries management and suggest a potential adjunctive role within preventive dentistry strategies, particularly in selected high-risk populations.
- Open Access
- 1 January 2026
- Published by Wiley in Pain Research and Management
- Vol. 2026 (1)
Therapeutic Interventions to Manage Oral Mucositis and Their Impact on Quality of Life in Cancer Patients: An Umbrella Review
Background: Oral mucositis (OM) is a debilitating complication of cancer therapy, particularly in head and neck cancer patients, with significant adverse effects on quality of life (QoL). Although numerous interventions have been investigated, their impact on QoL remains inconsistently reported and poorly synthesized. Methods: An umbrella review was conducted following PRISMA 2020 and Joanna Briggs Institute (JBI) guidelines. Five databases (PubMed, Embase, Scopus, Web of Science, and Cochrane Library) were searched from inception to March 2024. Reviews were eligible if they evaluated any therapeutic intervention for OM and reported QoL‐related outcomes using validated tools. Methodological quality was appraised using AMSTAR 2, and findings were narratively synthesized and thematically categorized. The protocol was registered in PROSPERO (CRD420251044088). Results: Eight systematic reviews (257 primary studies) met the inclusion criteria. Photobiomodulation, honey, black mulberry, and botanical agents such as SAMITAL showed consistent improvement in QoL domains, including pain relief, oral function, and emotional well‐being. Gabapentin demonstrated potential in reducing opioid use and early mucositis‐related pain, though findings were mixed across trials. QoL was most commonly assessed using the EORTC QLQ‐C30, FACT‐HN, and UW‐QOL. Overall, heterogeneity in intervention protocols and QoL instruments limited comparability. Conclusions: This review highlights the most promising interventions for improving QoL in patients with OM. Standardizing QoL measurement and prioritizing patient‐reported outcomes in future trials is essential to inform evidence‐based supportive oncology care.
- 1 January 2026
- Published by Wiley in Pain Research and Management
- Vol. 2026 (1)
Open AccessTherapeutic Interventions to Manage Oral Mucositis and Their Impact on Quality of Life in Cancer Patients: An Umbrella Review
Background: Oral mucositis (OM) is a debilitating complication of cancer therapy, particularly in head and neck cancer patients, with significant adverse effects on quality of life (QoL). Although numerous interventions have been investigated, their impact on QoL remains inconsistently reported and poorly synthesized. Methods: An umbrella review was conducted following PRISMA 2020 and Joanna Briggs Institute (JBI) guidelines. Five databases (PubMed, Embase, Scopus, Web of Science, and Cochrane Library) were searched from inception to March 2024. Reviews were eligible if they evaluated any therapeutic intervention for OM and reported QoL‐related outcomes using validated tools. Methodological quality was appraised using AMSTAR 2, and findings were narratively synthesized and thematically categorized. The protocol was registered in PROSPERO (CRD420251044088). Results: Eight systematic reviews (257 primary studies) met the inclusion criteria. Photobiomodulation, honey, black mulberry, and botanical agents such as SAMITAL showed consistent improvement in QoL domains, including pain relief, oral function, and emotional well‐being. Gabapentin demonstrated potential in reducing opioid use and early mucositis‐related pain, though findings were mixed across trials. QoL was most commonly assessed using the EORTC QLQ‐C30, FACT‐HN, and UW‐QOL. Overall, heterogeneity in intervention protocols and QoL instruments limited comparability. Conclusions: This review highlights the most promising interventions for improving QoL in patients with OM. Standardizing QoL measurement and prioritizing patient‐reported outcomes in future trials is essential to inform evidence‐based supportive oncology care.
- 15 December 2025
- Published by Wiley in European Journal of Oral Sciences
- Vol. 134 (2) , e70061
Effect of probiotic supplementation on the progression of non‐cavitated carious lesions in children: A 12‐month randomized controlled trial
This double‐blind, placebo‐controlled, cluster‐randomized clinical trial evaluated the effectiveness of daily Lactobacillus rhamnosus SP1 supplementation in reducing caries progression in preschool children. A total of 205 children aged 2–3 years from 10 public nursery schools in Santiago, Chile, were randomized by nursery school clusters (1:1) to receive either probiotic‐supplemented milk (1 × 10 7 CFU/mL) or standard milk once daily for 10 months. Examinations were conducted at baseline and 12 months using ICDAS criteria. The primary outcome was the proportion of children whose caries status progressed to cavitated lesions (ICDAS 5–6). Progression occurred in 26.8% of children in the probiotic group (33/123) and 46.3% in the control group (38/82). Surface‐level transitions were minimal in both groups and are reported descriptively. No intervention‐related adverse events were observed, and adherence exceeded 80%. Daily consumption of milk supplemented with L. rhamnosus SP1 for 10 months reduced the number of preschool children who developed cavitated carious lesions over a 12‐month period and may represent a safe and feasible adjunct for community‐based prevention of early childhood caries. The trial was prospectively registered at ClinicalTrials.gov (NCT01648075).
- 15 December 2025
- Published by Wiley in European Journal of Oral Sciences
- Vol. 134 (2) , e70061
Effect of probiotic supplementation on the progression of non‐cavitated carious lesions in children: A 12‐month randomized controlled trial
This double‐blind, placebo‐controlled, cluster‐randomized clinical trial evaluated the effectiveness of daily Lactobacillus rhamnosus SP1 supplementation in reducing caries progression in preschool children. A total of 205 children aged 2–3 years from 10 public nursery schools in Santiago, Chile, were randomized by nursery school clusters (1:1) to receive either probiotic‐supplemented milk (1 × 10 7 CFU/mL) or standard milk once daily for 10 months. Examinations were conducted at baseline and 12 months using ICDAS criteria. The primary outcome was the proportion of children whose caries status progressed to cavitated lesions (ICDAS 5–6). Progression occurred in 26.8% of children in the probiotic group (33/123) and 46.3% in the control group (38/82). Surface‐level transitions were minimal in both groups and are reported descriptively. No intervention‐related adverse events were observed, and adherence exceeded 80%. Daily consumption of milk supplemented with L. rhamnosus SP1 for 10 months reduced the number of preschool children who developed cavitated carious lesions over a 12‐month period and may represent a safe and feasible adjunct for community‐based prevention of early childhood caries. The trial was prospectively registered at ClinicalTrials.gov (NCT01648075).